ELVN
ELVN
US29337E1029
Enliven Therapeutics, Inc.
Loading chart...

Financials

Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
Breakdown 2025 2024 Change %
Total Revenue -- --
--
Cost of Revenue -- --
--
Gross Profit -- --
--
119.658.000 104.554.000
14.4%
Operating Income -119.658.000 -104.554.000
14.4%
Pretax Income -103.694.000 -88.792.000
16.8%
Net Income Common Stockholders -103.694.000 -89.024.000
16.5%
-- --
--
-- --
--
ende